Techdirt. Stories filed under ".pharmacy"Easily digestible tech news...https://www.techdirt.com/
en-usTechdirt. Stories filed under ".pharmacy"https://ii.techdirt.com/s/t/i/td-88x31.gifhttps://www.techdirt.com/Tue, 5 Aug 2014 05:48:00 PDTBig Pharma Given Control Of New .pharmacy Domain; Only Available To 'Legitimate' Online PharmaciesGlyn Moodyhttps://www.techdirt.com/articles/20140802/03175328088/big-pharma-given-control-new-pharmacy-domain-only-available-to-legitimate-online-pharmacies.shtml
https://www.techdirt.com/articles/20140802/03175328088/big-pharma-given-control-new-pharmacy-domain-only-available-to-legitimate-online-pharmacies.shtml
Just over a year ago, Techdirt reported on big pharma's application to run a new .pharmacy domain, and later on an attempt by Canadian pharmacies to prevent that happening. They failed, apparently (found via Intellectual Property Watch):

As the registry operator of the new .pharmacy domain, the National Association of Boards of Pharmacy (NABP), under a contract with the Internet Corporation for Assigned Names and Numbers (ICANN), will soon provide a means for identifying safe online pharmacies and resources. Under the Association’s Registry Agreement, executed with ICANN on June 19, 2014, the new .pharmacy generic Top-Level Domain (gTLD) will be available only to legitimate online pharmacies and related entities located in the United States or other countries. The Registry Agreement also includes a number of safeguards intended to protect consumers around the world.

The question is: what will "only available to legitimate online pharmacies" and "intended to protect consumers" mean in practice? The concern is that these are euphemisms for big pharma shutting out those competitors offering lower-cost products, particular foreign pharmacies, and manufacturers of generics. That fear is not assuaged by the following comment from the NABP in its response to such concerns (pdf)

the .PHARMACY TLD will provide a powerful tool to educate consumers, distinguish legitimate Internet pharmacies from the thousands of rogue Internet drug outlets, and reinforce the value of purchasing medications only from trusted online sources.

Big pharma is clearly as keen as the copyright industries to "educate" consumers about what they ought to be doing. The danger here is that such "education" will include not trusting perfectly safe pharmacies outside the US (in Canada, for example), and not using much cheaper generics. Since NABP now controls this entire domain it will have a free hand to block any outfit that does not subscribe to those views, and thus to attempt to delegitimize them in the eyes of the consumer.

This is something new. Hitherto, there has been no danger of this kind of discrimination against particular classes of Internet users, since registry operators were focused on maximizing profits by getting as many domains issued as possible. That won't be the case for .pharmacy, where the aim is to police the online pharmacy world, and to protect the generous profits of big pharma -- not make a few dollars selling a domain or two. Assuming that happens, we can probably expect other industries to follow suit in creating and controlling new domains, and for the Internet to become less free and neutral.

Permalink | Comments | Email This Story
]]>guess-who-they-will-behttps://www.techdirt.com/comment_rss.php?sid=20140802/03175328088Fri, 17 May 2013 09:29:43 PDTBig Pharma Firms Seeking .pharmacy Domain To Crowd Out Legitimate Foreign PharmaciesMike Masnickhttps://www.techdirt.com/articles/20130515/00145123090/big-pharma-firms-seeking-pharmacy-domain-to-crowd-out-legitimate-foreign-pharmacies.shtml
https://www.techdirt.com/articles/20130515/00145123090/big-pharma-firms-seeking-pharmacy-domain-to-crowd-out-legitimate-foreign-pharmacies.shtmlconflate legitimate foreign pharmacies (often based in Canada) that sell back into the US (the so-called "reimportation" or "parallel import" market) at cheaper prices with out and out bogus or counterfeit online pharmacies. The drug companies like nothing better than when people lump the two very different beasts together and label them all as "counterfeit." Of course, for many Americans, relying on cheaper legit drugs from Canada is the only way they can survive, and there have been efforts made at times by US politicians -- including President Obama -- to support more parallel importation to ease the high cost of drugs in the US.

However, there's an interesting tidbit coming out in the ongoing battles over new top level domains. It appears that the National Association of Boards of Pharmacy is seeking a .pharmacy domain, which (obviously) they would then only bestow upon pharmacies that they like. That could be a big issue, because it's likely they wouldn't allow that for certain Canadian pharmacies and other foreign legitimate pharmacies that may offer cheaper drugs. Both Demand Progress and Public Citizen recently filed comments with ICANN about why NABP should not be allowed to control .pharmacy.

Granting the .pharmacy domain to NABP would confer legitimacy on pharmacies sanctioned by NABP, to the detriment of those that are not.

NABP has proposed an unfair standard that would bar online pharmacies that serve US consumers but are located outside of the United States from using the domain (see NABP’s application at Section 18(a) IV*). This would exclude many licensed pharmacies which offer American consumers low-cost medicines of quality.

Whether a pharmacy is located in the United States does not determine whether a pharmacy is licensed and provides medicines of quality.

Consumer access to medicines depends in significant part on price and competition. It would be inappropriate to allow NABP to control such an important gTLD while it maintains exclusionary plans for the domain, which work against the consumer interest in a robust market of quality affordable pharmaceuticals.

The pharmaceutical industry has prioritized trying to shut down legitimate pharmacies selling safe Canadian drugs to U.S. consumers (as currently allowed by the U.S. Food and Drug Administration). But their tactics to achieve these anti-consumer goals involve censorship regimes allowing government seizure of domains, blacklists of sites, or suspended hosting services for legitimate competitors.

NABP supporters have justified their actions by preying on consumer fear of counterfeiters, when their real goals include shutting down sites providing cheaper legitimate drugs. Pfizer joined the assault on the Net in 2011, testifying to Congress that: "The major threat to patients in the U.S., however, is the Internet..." ...

NABP's supporters define "fake pharmacies" as those not registered with VIPPS, rather than only those selling actual counterfeit goods.

The Demand Progress comment also points out how the big pharmaceutical companies supported SOPA and PIPA, since they knew that it, too, would be useful to use as a sledgehammer against foreign online pharmacies that sold legitimate drugs back into the US.